Zargar-Shoshtari Kamran, Kim Timothy, Simon Ross, Lin Hui-Yi, Yue Binglin, Sharma Pranav, Spiess Philippe E, Poch Michael A, Pow Sang Julio, Sexton Wade J
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
Department of Biostatistics, Moffitt Cancer Center, Tampa, FL.
Urology. 2015 Aug;86(2):321-6. doi: 10.1016/j.urology.2015.05.013. Epub 2015 Jul 15.
To assess the pattern of renal cell carcinoma (RCC) recurrences in nephron-sparing surgery (NSS) patients, and to determine whether current guidelines for surveillance could be modified based on such patterns.
Retrospective review of a single-institution NSS database. Pattern of RCC recurrences and factors associated with recurrence were analyzed using univariate and multivariable competing risk regression analyses. Cost of surveillance was estimated based on Medicare charges.
A total of 505 patients underwent elective NSS for RCC. Pathologic T stage included 394 pT1a and 79 pT1b lesions. Median follow-up was 38.3 (6-88) months. Recurrence was detected in 26 patients (5.1%) at a median of 18.9 months (2.7% pT1a and 12.7% pT1b). The estimated 5-year cumulative incidence of recurrence for unifocal pT1a lesions was 2.7%. On multivariable analysis, stage higher than pT1a (HR, 5.56 [CI. 2.57-12.0]) and the presence of multifocal or bilateral tumors (HR, 3.32 [CI, 1.45-7.61]) were independent predictors of disease recurrence. For the entire cohort, recurrence was observed in only 10 patients beyond 24 months including only 2 cases with pT1a.
Current guidelines adequately capture most clinically significant recurrences, and with longer follow-up, it may be possible to confirm that routine surveillance beyond 2 years may have little clinical significance for patients with asymptomatic unifocal pT1a.
评估保留肾单位手术(NSS)患者肾细胞癌(RCC)复发模式,并确定能否基于这些模式修改当前的监测指南。
对单机构NSS数据库进行回顾性分析。采用单因素和多因素竞争风险回归分析RCC复发模式及与复发相关的因素。根据医疗保险费用估算监测成本。
共有505例患者因RCC接受择期NSS。病理T分期包括394例pT1a和79例pT1b病变。中位随访时间为38.3(6 - 88)个月。26例患者(5.1%)出现复发,中位复发时间为18.9个月(pT1a为2.7%,pT1b为12.7%)。单灶性pT1a病变的估计5年累积复发率为2.7%。多因素分析显示,高于pT1a期(HR,5.56 [CI,2.57 - 12.0])以及存在多灶性或双侧肿瘤(HR,3.32 [CI,1.45 - 7.61])是疾病复发的独立预测因素。对于整个队列,仅10例患者在24个月后出现复发,其中只有2例pT1a患者。
当前指南充分涵盖了大多数具有临床意义的复发情况,且随着随访时间延长,可能证实对于无症状单灶性pT1a患者,2年以上的常规监测可能临床意义不大。